{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:16:09Z","timestamp":1793686569245,"version":"4.5.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105515","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:39:49Z","timestamp":1786059589000},"page":"105515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Conversion strategies in RAS wild-type colorectal liver metastases: a systematic review and meta-analysis of first-line trials comparing regimens with anti-epidermal growth factor receptor inhibitors versus bevacizumab"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-0233","authenticated-orcid":false,"given":"Salvatore","family":"Corallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Cicerone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Brigati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Colletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Pellizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105515_bib1","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105515_bib2","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105515_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10585-025-10357-y","article-title":"The challenge of disappearing colorectal liver metastasis: balancing considerations between tumor biology and clinical consequence for liver surgery","volume":"42","author":"Ansari","year":"2025","journal-title":"Clin. Exp. Metastas."},{"key":"10.1016\/j.critrevonc.2026.105515_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib5","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s12094-025-03887-0","article-title":"HER2-targeted therapy in colorectal cancer: a comprehensive review","volume":"27","author":"Benli","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","volume":"24","author":"Bond","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jamaoncol.2024.5174","article-title":"First-line systemic treatment for initially unresectable colorectal liver metastases: post hoc analysis of the CAIRO5 Randomized Clinical Trial","volume":"11","author":"Bond","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102926","article-title":"EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases","volume":"136","author":"Bregni","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105515_bib9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.annonc.2024.05.016","article-title":"5MO Individual patient data (IPD) meta-analysis of randomised phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145","volume":"35","author":"Bregni","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Bridgewater","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2022.01.012","article-title":"Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment","volume":"168","author":"Buisman","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.111155","article-title":"Anti-EGFR plus chemotherapy vs. chemotherapy alone in RAS wild-type colorectal liver metastases: a meta-analysis of survival outcomes in resectable and unresectable settings","volume":"52","author":"Cicerone","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib14","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.surg.2018.01.004","article-title":"Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?","volume":"163","author":"Creasy","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.critrevonc.2026.105515_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","author":"Cremolini","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib16","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105515_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib18","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","article-title":"Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)","volume":"51","author":"Heinemann","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib19","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","article-title":"FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial","volume":"124","author":"Heinemann","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115388","article-title":"FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: refining first-line treatment selection by combining clinical parameters: a post hoc analysis of the randomized open-label phase III trial FIRE-3\/AIO KRK0306","volume":"220","author":"Holch","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials","volume":"70","author":"Holch","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ijc.31114","article-title":"Relevance of liver-limited disease in metastatic colorectal cancer: subgroup findings of the FIRE-3\/AIO KRK0306 trial","volume":"142","author":"Holch","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1323-9","article-title":"Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)","volume":"15","author":"Huiskens","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105515_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2020.11.017","article-title":"Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer","volume":"144","author":"Manca","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.dld.2019.03.028","article-title":"Quantitative evaluation of liver metastases density on computed tomography: a new tool to evaluate early response to bevacizumab-containing chemotherapy","volume":"51","author":"Mazard","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.critrevonc.2026.105515_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.critrevonc.2026.105515_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2017.10.028","article-title":"Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer\u2014central evaluation of FIRE-3","volume":"88","author":"Modest","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib30","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative Hyperselection of Patients With RAS and BRAF Wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2468-1253(23)00479-X","article-title":"Targeting the EGFR signalling pathway in metastatic colorectal cancer","volume":"9","author":"Napolitano","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib32","article-title":"KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials","volume":"9","author":"Navarro-Jim\u00e9nez","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41416-019-0518-2","article-title":"Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)","volume":"121","author":"Oki","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438466","article-title":"State-of-the-Art management of colorectal cancer: treatment advances and innovation","volume":"44","author":"Pathak","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.critrevonc.2026.105515_bib35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1470-2045(14)70105-6","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial","volume":"15","author":"Primrose","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib36","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1245\/s10434-025-18922-1","article-title":"Oncological Adequacy of R1 Vascular Margin in Minimally Invasive Liver Surgery for Hepatocellular Carcinoma and Colorectal Liver Metastases: A Meta-analysis","volume":"33","author":"Procopio","year":"2026","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib37","article-title":"Negative Ultraselection of Patients With RAS\/BRAF wild-type, microsatellite-stable metastatic colorectal cancer receiving anti-EGFR-Based Therapy","volume":"6","author":"Randon","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","article-title":"Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma","volume":"32","author":"Rivera","year":"2017","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.critrevonc.2026.105515_bib39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","article-title":"Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials","volume":"184","author":"Rossini","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105515_bib40","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54460-2","article-title":"Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial","volume":"15","author":"Shiozawa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105515_bib42","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105515_bib43","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105515_bib44","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105515_bib45","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"LANCET Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib46","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.annonc.2025.05.047","article-title":"35P Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab by metastasis status in RAS\/BRAF wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13)","volume":"36","author":"Sunakawa","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105515_bib47","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105515_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184392","article-title":"Pathological evaluation of resected colorectal liver metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial","volume":"14","author":"Takahashi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105515_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042366","article-title":"NTRK therapy among different types of cancers, review and future perspectives","volume":"25","author":"Theik","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105515_bib50","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2026.105515_bib51","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival among Patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105515_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113975","article-title":"A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness","author":"Yoshino","year":"2024","journal-title":"Eur. J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:51:29Z","timestamp":1793087489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":52,"alternative-id":["S1040842826004026"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105515","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conversion strategies in RAS wild-type colorectal liver metastases: a systematic review and meta-analysis of first-line trials comparing regimens with anti-epidermal growth factor receptor inhibitors versus bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105515"}}